Skip to main content
Tuesday, November 17, 2026Nov 17

Popular weight-loss drugs like Wegovy may raise risk of complications under anesthesia

FILE - Instruments sit on a table in an operating room June 15, 2023, in Jackson, Tenn. Patients who take blockbuster drugs like Wegovy for weight loss may face life-threatening complications if they need surgery or other procedures that require empty stomachs for anesthesia. In June 2023, the American Society of Anesthesiologists issued guidance advising patients to skip daily weight-loss medications on the day of surgery and hold off on weekly injections for a week before any sedation procedures. (AP Photo/Mark Humphrey, File)
FILE - Instruments sit on a table in an operating room June 15, 2023, in Jackson, Tenn. Patients who take blockbuster drugs like Wegovy for weight loss may face life-threatening complications if they need surgery or other procedures that require empty stomachs for anesthesia. In June 2023, the American Society of Anesthesiologists issued guidance advising patients to skip daily weight-loss medications on the day of surgery and hold off on weekly injections for a week before any sedation procedures. (AP Photo/Mark Humphrey, File)

Patients who take blockbuster drugs like Wegovy or Ozempic for weight loss may face life-threatening complications if they need surgery or other procedures that require empty stomachs for anesthesia. This summer’s guidance to halt the medication for up to a week may not go far enough, either.

Some anesthesiologists in the U.S. and Canada say they’ve seen growing numbers of patients on the weight-loss drugs who inhaled food and liquid into their lungs while sedated because their stomachs were still full — even after following standard instructions to stop eating for six to eight hours in advance.

The drugs can slow digestion so much that it puts patients at increased risk for the problem, called pulmonary aspiration, which can cause dangerous lung damage, infections and even death, said Dr. Ion Hobai, an anesthesiologist at Massachusetts General Hospital in Boston.

“This is such a serious sort of potential complication that everybody who takes this drug should know about it,” said Hobai, who was among the first to flag the issue.

Nearly 6 million prescriptions for the class of drugs that include Wegovy and Ozempic were written between January and May in the U.S. for people who don’t have diabetes, according to Komodo Health, a health care technology company. The drugs induce weight loss by mimicking the actions of hormones, found primarily in the gut, that kick in after people eat. They also target signals between the gut and the brain that control appetite and feelings of fullness, and by slowing how fast the stomach empties.